This transcript has been edited for clarity.
Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York City. It is my great pleasure to welcome my friend, colleague, and close collaborator, also from Weill Cornell Medicine, Dr Pinkal Desai. Pinkal, thank you so much for joining today.
Pinkal Desai, MD, MPH: It is my absolute pleasure.
Roboz: Today we're going to talk about intermediate-risk acute myeloid leukemia (AML). AML is a difficult disease, and it basically comes in three flavors: good, bad, and medium, or favorable, intermediate, and adverse risk. This is a gross oversimplification, but the truth is that intermediate-risk disease really includes the majority of AML patients. I think it's very, very important for the audience to understand the classification of AML patients because this is what really drives not only the prognosis but also therapeutic decision-making. Pinkal, what do we mean by intermediate risk, what classification should we be using, and who's included in that category?
Desai: Two things come up. One is the European LeukemiaNet (ELN) intermediate riskwhich basically takes into account both the cytogenetics and the molecular mutations.
